Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $41,076.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $318.55 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The stock’s 50 day simple moving average is $274.77 and its 200-day simple moving average is $244.09. The company has a market cap of $14.13 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 4.77 and a beta of 0.49. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $321.80.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter last year, the firm posted $4.86 EPS. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Rise Advisors LLC acquired a new position in United Therapeutics during the first quarter worth $32,000. GAMMA Investing LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. boosted its position in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 117 shares during the last quarter. Janiczek Wealth Management LLC grew its holdings in shares of United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 84 shares during the period. Finally, Blue Trust Inc. increased its position in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 46 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. Oppenheimer upped their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Finally, Wells Fargo & Company raised their target price on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $312.22.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.